logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Retrophin Raises Offer to Acquire Transcept Pharmaceuticals to $4 Per Share

By  +Follow September 19, 2013 8:51AM
Share:
Tickers Mentioned:

Retrophin, Inc. (RTRX) is not giving up on its pursuit to acquire the shares of specialty drug maker Transcept Pharmaceuticals, Inc. (TSPT) that it does not already own.  Last week, Retrophin delivered a letter to the board of directors of Transcept offering to buy the remaining shares for $3.50 each in cash.  The offer was rejected. 

To defend itself from a hostile takeover, Transcept has adopted a shareholder rights plan, often called a “poison pill,” which keeps a shareholder from acquiring more than 4.99 percent of the company.

On Wednesday, Retrophin bumped the offer up to $4.00 per share, with Retrophin chief executive Martin Shkreli sending a letter to the board members of Transcept.

Transcept is focused on development of neuroscience drugs with its only FDA approval being the oral sleep aid Intermezzo (zolpidem tartrate).  Purdue Pharma holds commercialization and development right for Intermezzo in the U.S.  Royalty revenue for Transcept from Intermezzo in the first six months of 2013 was $1.0 million, up from $500,000 in the year prior period. 

Net loss for the six months ended June 30, 2013 was approximately $17.2 million, or $0.92 per share, versus a net loss of approximately $10.3 million, or $0.67 per share, for the six months of 2012.

Retrophin has four drugs in its pipeline with RE-021 the only one in the clinical stage, being researched in a mid-stage trial for Focal Segmental Glomerulosclerosis, a disease that can cause nephrotic syndrome in children and kidney failure in adults.  The company’s other compounds are targeting hard-to-treat diseases like Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy.

In recent weeks, three major shareholders of Transcept have publicly stated their disapproval of Transcept’s current strategy.  Activist investor Peter Collery of SC Fundamental LLC, which owns a 6.7-percent stake in Transcept, sent a letter to Transcept chief executive, president and director Glenn Oclassen (read the SEC filing) saying that the company needs to use $60 million of its cash to conduct a share repurchase to build value, not pursue “simply wrongheaded,” (but unnamed) projects.

Collery didn’t hold back much in expressing his feelings toward Transept management.  Such as:

“I should note how troubled we are by your presumption that the company’s money is yours to do with as you see fit. You and your fellow directors have a fiduciary duty to company shareholders.”

And...

“I’d like, in closing, also to express my displeasure with the company’s recent grant of nearly 600,000 management stock options with a strike price of $2.93 per share. As described above, the company’s shares may have a current realizable value of $5 or so. Were Transcept to implement a buyback program, that value might rise to $6. Essentially no management skill would be required to realize these values. That the shares trade for less than $3 is a function of shareholders’ distrust of management. It is incredible that management should be granted undervalued stock options as a “reward” for having created that distrust and I would expect that an inquiry into the deliberations surrounding this recent option grant, and particularly, the suitability of the strike price would be quite interesting.”

Roumell Asset Management, LLC, the largest Transcept shareholder at 12.3 percent of the company, has also filed a 13D with the SEC criticizing the management and demanding a share buy-back plan, not an unidentified acquisition.

The new proposal by Retrophin offers to buy Transcept at a 20-percent premium to Tuesday’s closing price.  The price is still lower than the $6 mark that Collery believes can be attained by performing a share repurchase, but this is a little to-may-toes/to-ma-toes because a merged company could benefit similarly, so investors will have to see where the support falls with the new proposal.

“Our proposal represents an attractive premium to Transcept’s trading performance, and we believe that the proposal offers a compelling opportunity for Transcept’s stockholders, particularly in light of Transcept’s risky and controversial acquisition strategy,” stated Martin Shkreli, Chief Executive Officer of Retrophin. “We hope that Transcept’s Board of Directors will respect its stockholders’ wishes and quickly commence discussions with us regarding the proposed transaction.”

Retrophin wants a transaction to be entered into by the end of September.

Shares of TSPT are down about 18 percent in 2013 thanks to a run-up from lows of $2.52 late in August with the acquisition chatter.  At lows, the stock was off about 40 percent.  Shares rose by 8 percent in Wednesday trading to close at $3.59.  In extended trading, shares rose to $3.98.  Retrophin shares edged up about 1 percent on the day to $6.88.  Shares have more than doubled in 2013.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for rtrx
Stockaholics
20 Oct 14 20:30:07
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
Stockaholics
20 Oct 14 16:49:41
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
Stockaholics
20 Oct 14 12:14:22
After Massive Gains On Penny Stock Picks, another New Pick Is Coming! Check it out: http://t.co/YX0NLZhRQ5 $RTRX $CPST $TGTX
Bryan Campbell
20 Oct 14 09:09:44
RT @MKerryFuller: $RTRX when does @adamfeuerstein do his annual worst CEO list? I have a nomination for him.
mohamed
20 Oct 14 08:38:57
@MartinShkreli hello Martin, how can I access $RTRX conference call, I HEARD YOU WILL BE PARTICIPAING, CANT WAIT TO HEAR FROM YOU
Patrick
20 Oct 14 07:45:29
RT @vram2000: $RTRX My Q3 revenue estimate: $12-15MM. We should c Thiola sales. Q3 conf call should be interesting. Will they let @MartinSh…
Martin Shkreli
20 Oct 14 07:29:23
@ColfaxCapital @vram2000 will start commenting a bit on $RTRX soon. i think the stock is very cheap. not selling anytime soon unless i must
BioInvestor
20 Oct 14 07:09:50
$RTRX My Q3 revenue estimate: $12-15MM. We should c Thiola sales. Q3 conf call should be interesting. Will they let @MartinShkreli ask Q's?
Stockaholics
19 Oct 14 23:48:51
After Massive Gains On Penny Stock Picks, another New Pick Is Coming! Check it out: http://t.co/YX0NLZhRQ5 $RTRX $CPST $TGTX
Stockaholics
19 Oct 14 16:46:04
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
nixon786
19 Oct 14 11:52:52
@Thug_BioAnalyst Heard he left $RTRX
Stockaholics
18 Oct 14 14:00:57
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
Stockaholics
18 Oct 14 11:28:33
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
Stockaholics
18 Oct 14 03:18:14
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
Yu Zhu
17 Oct 14 15:50:34
RT @BentheFidler: East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More http://t.co/dxS7Ogeh78 $ALNY $RTRX $BLUE $EPZM $ZFGN $SAGE …
OTC Alerts
17 Oct 14 15:24:50
$RTRX received a new alert.See why at http://t.co/FwU0sYdHLW $MSEZ #Penny #pennystocks #PinkSheet #OTC #OTCBB #stocks #stock 122
equities.com
17 Oct 14 15:22:41
RETROPHIN INC (RTRX) Drops 7.01% on October 17 $rtrx http://t.co/VzYZLswYZ4
Stockaholics
17 Oct 14 13:12:13
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
Stockaholics
17 Oct 14 01:08:39
Platinum Penny Stock Picks Gained 125% last week! New Pick Coming Today! Check It Out: http://t.co/7gQJ2ZCjuq $RTRX $CPST $TGTX
Bank
17 Oct 14 00:29:22
@Thug_BioAnalyst $RTRX?
Stockaholics
16 Oct 14 21:30:21
Platinum Penny Stock Picks Gained 125% last week! New Pick Coming Today! Check It Out: http://t.co/7gQJ2ZCjuq $RTRX $CPST $TGTX
Stockaholics
16 Oct 14 17:48:28
ABPI Gained 1,587.50% In 3 days! Big News: http://t.co/7gQJ2ZCjuq $RTRX $CPST $TGTX
Ram Lanka
16 Oct 14 15:00:38
@given2tweet Hilarious to see people who were involved with $RTRX commenting on $SRPT #credibilityissue?
Gavin Parks
16 Oct 14 13:19:20
RT @given2tweet: Yah your old company, $RTRX is real blue chip! RT: @chasingthealpha $SRPT charade continues #NonNonNonGAAPEarnings
Stockaholics
16 Oct 14 10:30:57
ABPI Gained 1,587.50% In 3 days! Big News: http://t.co/7gQJ2ZCjuq $RTRX $CPST $TGTX
Big3Bio:Boston
16 Oct 14 09:08:11
RT @BentheFidler: East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More http://t.co/dxS7Ogeh78 $ALNY $RTRX $BLUE $EPZM $ZFGN $SAGE …
Ben Fidler
16 Oct 14 09:04:58
East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More http://t.co/dxS7Ogeh78 $ALNY $RTRX $BLUE $EPZM $ZFGN $SAGE $INFI $IRWD
Stockaholics
16 Oct 14 00:19:15
ABPI Gained 1,587.50% In 3 days! Big News: http://t.co/7gQJ2ZCjuq $RTRX $CPST $TGTX
Zachary Prensky
15 Oct 14 10:17:52
@ohmsonite ve high prob onRE-024. Bio-Markers don't lie. $RTRX setting up for explosive move in'15 on poten. + FSGS/PKAN data IN THE CLINIC!
Stockaholics
15 Oct 14 10:07:47
ABPI Gained 1,587.50% In 3 days! Big News: http://t.co/7gQJ2ZCjuq $RTRX $CPST $TGTX
Zachary Prensky
15 Oct 14 07:23:12
Nice to see $RTRX outperform today. Like the divestiture announced yesterday and the focus on getting FSGS & RE-024 thru the clinic
Stockaholics
14 Oct 14 21:18:55
ABPI Gained 1,587.50% In 3 days! Big News: http://t.co/7gQJ2ZCjuq $RTRX $CPST $TGTX
Dan Wessler
14 Oct 14 19:26:46
@Thug_BioAnalyst @BioStocks He's the new CET of $RTRX.
Stockaholics
14 Oct 14 14:24:30
Our Penny Stock Alerts Gained Over 570% Within the past 6 Trading Days! New Picks Coming: http://t.co/OHPRpgNMTU $RTRX $CPST $TGTX
4-traders.com
14 Oct 14 14:15:06
RETROPHIN : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers (form 8-K) http://t.co/NNlJJRqLTL $RTRX
Pzaa...Guy
14 Oct 14 14:12:33
$RTRX - Current Report Filing (8-k) http://t.co/ZVxgeP881G
Instrumental Data
14 Oct 14 14:09:39
RETROPHIN, INC. $RTRX 8-K now available
Sludge Reports
14 Oct 14 12:21:46
$RTRX Cheers to @MartinShkreli for getting what he wanted (or did he?) and starting his own private company. Congrats and farewell
Rob Wright
14 Oct 14 10:48:55
RT @BioStocks: $RTRX Announces Divestment of Non-Core Assets to Turing Pharmaceuticals http://t.co/yJBrGB4eaW
BuyersStrike
14 Oct 14 09:46:26
Actually @MartinShkreli and I agree on most things, just not $RTRX.
BuyersStrike
14 Oct 14 09:45:39
. @MartinShkreli and I might not agree on everything, but $RTRX without him is just a reverse merger turd w bad mgmt. Just see today's news.
BuyersStrike
14 Oct 14 09:44:07
Remember back in Dec 13 when $RTRX paid $5mm upfront just for Syntocinon? @MartinShkreli getting the very best end of this "divestiture".
Joe McCann
14 Oct 14 09:04:38
. @AceOfSpades2007 @vigkap Andrew, I'm sure that is correct-Martin doesn't get rights to work he did at $RTRX now that situation is resolved
Joe McCann
14 Oct 14 08:58:52
Well that's an interesting development at $RTRX - Let's hope this resolution gets the stock back over $20!
Brian Strizich
14 Oct 14 08:40:10
RT @chasingthealpha: $RARE at $2B mcap, $RTRX $450m mcap deeper pipeline and revenues. Much better risk/reward
Andrew Colburn
14 Oct 14 08:10:34
@vigkap since it was done under employment, I'm pretty sure $RTRX retains all rights. Like my grandpa and his patents at $X
hermann
14 Oct 14 07:52:37
$rtrx is returning Syntocinon Nasal Spray (oxytocin) and Vecamyl (mecamylamine HCI tablets) from Turing Pharmaceuticals for its $ back
YASHIRA GOUCHA
14 Oct 14 07:49:02
@MartinShkreli @stocksdd Will you be forced to liquidate your $RTRX shares?
Briefing.com
14 Oct 14 07:13:27
$RTRX: Retrophin announces divestment of non-core assets to Turing Pharmaceuticals; Turing will pay Retrophin a $3... http://t.co/IXWvX45Kp2
Stocks DD
14 Oct 14 07:13:26
@MartinShkreli good for you. Good luck to you. Is Turing going to go public in the near future ? $RTRX
				
				
By  +Follow September 19, 2013 8:51AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.